Multimorbidity, Cardiovascular DiseasesCHIPNCT06845397
Chuvashia Inappropriate Prescribing Study
An observational study of Multimorbidity, Cardiovascular Diseases, run by National Medical Research Center for Therapy and Preventive Medicine at 1 site in Russia.
Trial summary
This is a cross-sectional study based on an outpatient registry. All medical therapy will be registered in order to assess inappropriate prescribing's, in accordance with the criteria PROMPT and BEERS, also in accordance with the officially approved instructions for the use of this medicinal product. Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Multimorbidity, Cardiovascular Diseases
- How many people
- 300 participants
- Where
- 1 siteRussia
- Study dates
- 12 Dec 2023to 7 Aug 2024
- How long will I take part?
- 1 Month
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This is a cross-sectional study based on an outpatient registry. All medical therapy will be registered in order to assess inappropriate prescribing's, in accordance with the criteria PROMPT and BEERS, also in accordance with the officially approved instructions for the use of this medicinal product.
Who may be able to join
- Age > 50 years old, multimorbidity, signed Patients' Informed Consent
Who cannot join
- Age < 50 years, presence of mental illnesses, oncological diseases detected less than 5 years ago, acute cardiovascular pathology within 6 months prior to inclusion.
Trial locations and contacts
1 site in 1 country.
Russia1 site
Respublikanski Kardiologicheski Dispanser Minzdrava Chuvashii
Cheboksary
About this study
This is a cross-sectional study based on an outpatient registry. All medical therapy will be registered in order to assess inappropriate prescribing's, in accordance with the criteria PROMPT and BEERS, also in accordance with the officially approved instructions for the use of this medicinal product.
- Conditions
- Multimorbidity, Cardiovascular Diseases
- Keywords
- multimorbidity, self-medication, drugs, over-the-counter (OTC) drugs, prescription drugs, adherence, inappropriate prescribing
- Medical subject headings
- Cardiovascular Diseases, Ornithine Carbamoyltransferase Deficiency Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
frequency of inappropriate drug prescriptions
Рrescribing medications in an inadequate dose, with the wrong frequency, and the wrong duration of treatment, failure to prescribe a potentially effective drug in the presence of clinical indications, self-medication was considered irrational treatment and was assessed as the end point.
It also includes prescribing medications that are likely to have a negative effect on the course of concomitant pathology, as well as drug interactions, in accordance with the criteria PROMPT and BEERS.
Measured: Assessed at baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2025
- Study start12 Dec 2023
- Primary completion7 Aug 2024
- Study completion7 Aug 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multimorbidity, Cardiovascular DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 300 participants (actual)
- Target duration
- 1 Month
Sponsor and investigators
- Lead sponsor
- National Medical Research Center for Therapy and Preventive Medicine
- Sponsor type
- Other government
- Collaborators
- BU "Respublikanski Kardiologicheski Dispanser" Minzdrava Chuvashii, Cheboksary
- Responsible party
- Sponsor
- Investigators
- Sergey Martsevich, M.D., Professor, Study director, National Medical Research Centre for Therapy and Preventive Medicine, Moscow, Russia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06845397
- Sponsor's protocol ID
- 06-07/23
- Acronym
- CHIP
- Status last verified
- Jun 2025
- First submitted
- 20 Feb 2025
- Last updated
- 10 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Chuvashia Inappropriate Prescribing Study
- ClinicalTrials.gov ID
- NCT06845397
- Acronym / sponsor ID
- CHIP / 06-07/23
- Conditions
- Multimorbidity, Cardiovascular Diseases
- Keywords
- multimorbidity, self-medication, drugs, over-the-counter (OTC) drugs, prescription drugs, adherence, inappropriate prescribing
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 300 participants (actual)
- Lead sponsor
- National Medical Research Center for Therapy and Preventive MedicineOther government
- Collaborators
- BU "Respublikanski Kardiologicheski Dispanser" Minzdrava Chuvashii, Cheboksary
- Study start
- 12 Dec 2023 (actual)
- Primary completion
- 7 Aug 2024 (actual)
- Study completion
- 7 Aug 2024 (actual)
- First posted
- 25 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a cross-sectional study based on an outpatient registry. All medical therapy will be registered in order to assess inappropriate prescribing's, in accordance with the criteria PROMPT and BEERS, also in accordance with the officially approved instructions for the use of this medicinal product.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Month
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This is a cross-sectional study based on an outpatient registry. All medical therapy will be registered in order to assess inappropriate prescribing's, in accordance with the criteria PROMPT and BEERS, also in accordance with the officially approved instructions for the use of this medicinal product.
Key inclusion criteria (1 listed)
- Age > 50 years old, multimorbidity, signed Patients' Informed Consent
Key exclusion criteria (1 listed)
- Age < 50 years, presence of mental illnesses, oncological diseases detected less than 5 years ago, acute cardiovascular pathology within 6 months prior to inclusion.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
frequency of inappropriate drug prescriptions
Time frame: Assessed at baseline
Рrescribing medications in an inadequate dose, with the wrong frequency, and the wrong duration of treatment, failure to prescribe a potentially effective drug in the presence of clinical indications, self-medication was considered irrational treatment and was assessed as the end point. It also includes prescribing medications that are likely to have a negative effect on the course of concomitant pathology, as well as drug interactions, in accordance with the criteria PROMPT and BEERS.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jun 2025.
- Individual participant dataSharing planned: No
Related trials for Multimorbidity, Cardiovascular Diseases
Active, not recruiting
Community-Empowerment and Environmental Enrichment-based Co-management (CEEEC) Model and Mechanisms for Improving Health of Older Stroke Patients With Multimorbidity
Hypertension, Type 2 Diabetes Mellitus (T2DM)
RecruitingObservational study
Targeting Osteosarcopaenia and Multimorbidity for Frailty Prevention
Stroke, Traumatic Brain Injury
Recruiting
Transition to Cardiac Rehabilitation (T2CR) to Address Barriers of Multimorbidity and Frailty
Cardiovascular Diseases, Cardiac Rehabilitation
Active, not recruiting
Optimizing Prescribing Decisions for Hospitalized Older Adults With Chronic Conditions
Prescribing Decisions, Diabetes
Not yet recruiting
CEEEC-II: A 12-Week Physical and Cognitive Enrichment Extension Study in Older Stroke Survivors With Multimorbidity
Stroke, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sergey Martsevich, M.D., Professor study director
National Medical Research Centre for Therapy and Preventive Medicine, Moscow, Russia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Multimorbidity, Cardiovascular Diseases, run by National Medical Research Center for Therapy and Preventive Medicine at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
frequency of inappropriate drug prescriptions (time frame: Assessed at baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2025.